Table 2 Changes in the serum hormone levels in prostate cancer patients treated with a luteinizing hormone-releasing hormone agonist

T

Mean (ng/dL)

378.8 ± 145.1

9.6 ± 5.0

7.7 ± 4.6

P < 0.01 PRE vs, 12MO

Percentile change

-97.5%

-98.0%

DHT

Mean (pg/mL)

420.2 ± 200.2

21.6 ± 12.2

20.8 ± 11.2

P < 0.01 PRE vs 6MO, 12MO

Percentile change

-94.9%

-95.0%

E2

Mean (pg/mL)

16.2 ± 5.2

1.3 ± 1.0

1.4 ± 1.0

p < 0.01 PRE vs 6MO, 12MO

Percentile change

-92.2%

-91.3%

DHEA-S

Mean (μg/dL)

144.9 ± 66.6

107.2 ± 48.6

103.5 ± 54.3

P < 0.01 PRE vs 6MO, 12MO

Percentile change

-26.1%

-28.6%

DHEA

Mean (ng/mL)

1.85 ± 0.91

1.38 ± 0.67

1.29 ± 0.65

P < 0.01 PRE vs 6MO, 12MO

Percentile change

-25.1%

-30.0%

A-dione

Mean (pg/mL)

384.0 ± 133.5

231.7 ± 109.4

227.8 ± 119.7

p < 0.01 PRE vs 6MO, 12MO

Percentile change

-39.7%

-40.7%

cortisol

Mean (ng/mL)

89.9 ± 26.7

94.9 ± 27.4

81.4 ± 23.4

Not significant

Percentile change

5.4%

-10.4%